Antonin Bouchet, Brieuc Muller, Jerome Olagne, Thomas Barba, Mélanie Joly, Augustin Obrecht, Maud Rabeyrin, Frédérique Dijoud, Cécile Picard, Sarah Mezaache, Antoine Sicard, Alice Koenig, Anne Parissiadis, Valérie Dubois, Emmanuel Morelon, Sophie Caillard, Olivier Thaunat
Standard-of-care protocol, based on plasma exchanges, high dose IVIg, and optimization of maintenance immunosuppression can slow down the evolution of antibody-mediated rejection (AMR) but with high inter-individual variability. Identification of a reliable predictive tool of the response to AMR treatment is a mandatory step for the personalization of the follow-up strategy and to guide second line therapies. Interrogation of the electronic databases of 2 French University Hospitals (Lyon and Strasbourg) retrospectively identified 81 renal transplant recipients diagnosed with AMR without chronic lesions (cg ≤ 1) at diagnosis, and for whom a follow-up biopsy had been performed 3 to 6 months after initiation of therapy...
June 8, 2022: Nephrology, Dialysis, Transplantation